GKB Ophthalmics Quarterly Results
GKB Ophthalmics quarterly results. In Mar 2026, GKB Ophthalmics (GKB) reported revenue ₹31 Cr and net profit ₹1 Cr. Check GKB market value to track the company's total market size over time.
GKB Quarterly Results — Revenue, Profit & EPS Highlights
GKB Ophthalmics latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Review GKB P/E comparison to evaluate earnings-based valuation against sector peers.
- Revenue of ₹31 Cr in Mar 2026 (-8.8% vs Jun 2026, +0.0% vs Mar 2025)
- Net Profit of ₹1 Cr in Mar 2026 (-50.0% vs Jun 2026, +125.0% vs Mar 2025)
- EBITDA of ₹2 Cr in Mar 2026 (-33.3% vs Jun 2026)
- Operating Margin of 5.0% in Mar 2026 (-3.0pp vs Jun 2026)
- Earnings Per Share of ₹0.38 in Mar 2026 (-81.0% vs Jun 2026)
GKB Ophthalmics Quarterly Results — Revenue, EBITDA, Net Profit & EPS
GKB quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 31 | 34 | 31 | 31 | 33 | -8.8% | - |
| Net Profit (₹ Cr) | 1 | 2 | 2 | -4 | -1 | - | - |
| EBITDA (₹ Cr) | 2 | 3 | 3 | -3 | 1 | - | - |
| EPS (₹) | 0.38 | 2.00 | 3.17 | -7.03 | -2.02 | - | - |
| Operating Margin (%) | 5.0% | 8.0% | 10.0% | -9.0% | 2.0% | - | - |
GKB Share Price Trend — 1-Year Movement Across Quarterly Results
GKB Ophthalmics 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit GKB Ophthalmics screener.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
GKB vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
GKB Ophthalmics latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹432,120.23 Cr | 1779.7 | 15,018 | 2,710 | -5.6% | - | 18.0% | 157.5 |
|
Divis Laboratories
Mar 2026 |
₹244,124.91 Cr | 9196.0 | 2,986 | 751 | -5.0% | - | 25.2% | 324.8 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4772.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 414.6 |
|
Zydus Life Science
Mar 2026 |
₹113,615.69 Cr | 1139.0 | 7,569 | 1,341 | -4.3% | - | 17.7% | 90.0 |
|
Laurus Labs
Mar 2026 |
₹109,629.35 Cr | 1971.4 | 1,823 | 282 | -10.5% | - | 15.5% | 381.3 |
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores